Acute herpes zoster and post herpetic neuralgia in primary care: a study of diagnosis, treatment and cost

  • Brendan Crosbie
  • Sinead Lucey
  • Lesley Tilson
  • Lisa Domegan
  • Jennifer Kieran
Original Article


Acute herpes zoster and its complication post herpetic neuralgia represent a significant challenge to primary care physicians in their care of an ageing population of patients. This was a cross-sectional observational study by means of a quantitative survey of 1,000 general practitioners registered in Ireland exploring the frequency of diagnosis, methods of treatment and cost of AHZ and PHN in primary care. We recorded an 18% response rate (n = 184) with an 83% completion rate (n = 152/184). 80% of cases of AHZ occurred in patients aged 50 years or more with 81% of study participants encountering cases at a rate of 1–3 patients per month. Famciclovir (37%) and valaciclovir (36%) were the most commonly prescribed antiviral agents. Mild opioids (32%) were the most common analgesic agents used for first line AHZ pain, and pregabalin (37%) the most commonly prescribed analgesic agent for second line AHZ pain. Pregabalin was also the most commonly prescribed analgesic for both first and second line PHN pain (29% and 24%, respectively). The mean per-case direct cost (medication and GP visits) of treating AHZ and PHN in primary care was €195 (range €153–€236) and €201 (range €140–€313), respectively. Based on national sentinel data the estimated annual direct costs of treating AHZ and PHN in primary care is €2,278,196 (range €1,793,399–€2, 763,445). The treatment of AHZ and PHN represents both a significant care and cost burden on primary care resources in Ireland in keeping with other European based studies.



We would like to acknowledge the dedicated role of the Irish Sentinel GP network in gathering and summating patient data, in particular those involved in the surveillance of AHZ.

Compliance with ethical standards

Ethical approval

Ethical approval was not required as patients were not directly interacted with.

Informed consent

Informed consent was implied by survey participation.


  1. 1.
    Kawai K, Gebremeskel BG, Acosta CJ (2014) Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4:e004833CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lukas K, Edte A, Bertrand I (2012) The impact of herpes zoster and post herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Health 20:445–451CrossRefGoogle Scholar
  3. 3.
    Eurostat (2016) Population structure and ageing. (Data extracted June 2016). Accessed 04 December 2017
  4. 4.
    Oxman MN et al (2005) Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284CrossRefPubMedGoogle Scholar
  5. 5.
    Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF et al (2012) Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 54:922–928CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Brisson M, Pellissier JM, Levin MJ (2007) Cost-effectiveness of herpes zoster vaccine: flawed assumptions regard- ing efficacy against postherpetic neuralgia. Clin Infect Dis 45:1527–1529CrossRefPubMedGoogle Scholar
  7. 7.
    Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH et al (2010) Shingles prevention study group. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc 58:1634–1641CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R et al (2012) Shingles prevention study group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 55:1320–1328CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Szucs TD et al (2011) Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccine 7(7):749–756CrossRefGoogle Scholar
  10. 10.
    Health Service Executive (2017) PCRS Reimbursable Item List Website. Accessed on the 8 February 2017
  11. 11.
    Health Information and Quality Authority (2014) Guidelines for the economic evaluation of health technologies in Ireland 2014. HIQA. Available at Accessed on 8 February 2017
  12. 12.
    O’Kelly M et al (2015) Structure of general practice in Ireland 1982–2015. ICGP 2015 Accessed on the 8 February 2017
  13. 13.
    Ultsch B et al (2012) Epidemiology and cost of herpes zoster and post herpetic neuralgia in Germany. Eur J Health Econ 14(6):1015–1026CrossRefPubMedGoogle Scholar
  14. 14.
    Gater A, Uhart M, McCool R, Préaud E (2015) The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review. BMC Public Health. 15:193Google Scholar
  15. 15.
    Gialloreti et al (2010) Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infectious Disease 10:230CrossRefGoogle Scholar
  16. 16.
    Nilsson J, Cassel T, Lindquist L (2013) Burden of herpes zoster and post-herpetic neuralgia in Sweden. Value Health 16(7)Google Scholar
  17. 17.
    Scherdel P et al (2013) Growth monitoring: a survey of current practices of primary care paediatricians in Europe. Public Library of Science One 5:8(8)Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Trinity College DublinDublinIreland
  2. 2.National Centre for PharmacoeconomicsDublinIreland
  3. 3.Health Protection Surveillance CentreDublinIreland
  4. 4.Internal Medicine and Infectious Diseases Saint James Hospital DublinDublinIreland

Personalised recommendations